Skip to content
★ Sign in to follow
GM

Guanze Medical Information Industry (Holding) Co., Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$2.6BHealth Care

Guanze Medical Information Industry (Holding) Co., Ltd.: what insiders have been doing

Guanze Medical Information Industry (Holding) Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to HKEX. Between 23 October 2025 and 23 October 2026, 1 insider published 7 filings.

There is no open-market purchase to report; the filings show 7 sales worth €37.7M by 1 insider. At €19.0M, the sale published on 11 February 2026 by Meng Xianzhen is the largest of the period.

Typically, a trade is published a median of 1 day after it takes place. This delay matters because a trade only becomes useful information once it is public. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

For context, the typical company on the same exchange (median of 1,315 companies) published 4 filings over the same period, against 7 filings here. Since 2023, the database holds no purchases and 23 sales by insiders of the company.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Insider Decl.
24
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€38M
23 ops. · all time

Who traded when

BuySale
Meng Xianzhen10 sales

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 23,392 of 26,897 companies
24.8
score / 100
Value
32
Quality
17
FCF yld-0.3%
Earn yld-1.1%
EV/EBITDA·
ROE-31%
Gross mgn25%
Net mgn-34%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$2.76
Analyst consensus
·
Income statement
RevenueHK$88.4M
Gross profitHK$22.1M25% margin
EBITDA-HK$15.1M-17% margin
Net income-HK$29.7M-84.6% margin
Valuation
P/Book11.1x
Beta3.55
Balance sheet & cash
Market capHK$2.6B
Total debtHK$13.3M
Free Cash Flow-HK$9.2M
Debt / Equity8%
Profitability & ownership
ROE-31.2%
ROA-14.3%
% insiders73.6%
% institutions0.0%
Last declaration on 11 February 2026
Declarations24 total
  • ▼
    DirectorExecutives
    175M HKD16HKEX
    699,164,575 shares@ HK$0.2549.5% of flowShareXHKGHKEX:DA20260211E00215
  • ▼
    DirectorExecutives
    175M HKD16HKEX
    699,164,575 shares@ HK$0.2548.6% of flowShareXHKGHKEX:DA20260202E00061
  • ▼
    DirectorExecutives
    46,500 HKD11HKEX
    75,000 shares@ HK$0.620.0% of flowShareXHKGHKEX:DA20251210E00205
  • ▼
    DirectorExecutives
    124,000 HKD11HKEX
    200,000 shares@ HK$0.620.0% of flowShareXHKGHKEX:DA20251209E00029
  • ▼
    DirectorExecutives
    124,000 HKD11HKEX
    200,000 shares@ HK$0.620.0% of flowShareXHKGHKEX:DA20251205E00313
  • ▼
    DirectorExecutives
    24,052 HKD11HKEX
    40,000 shares@ HK$0.60130.0% of flowShareXHKGHKEX:DA20251201E00186
  • ▼
    DirectorExecutives
    72,600 HKD11HKEX
    120,000 shares@ HK$0.6050.0% of flowShareXHKGHKEX:DA20251119E00294
  • ▼
    DirectorExecutives
    40,110 HKD11HKEX
    105,000 shares@ HK$0.3820.0% of flowShareXHKGHKEX:DA20250701E00022
  • ▼
    DirectorExecutives
    188,670 HKD11HKEX
    570,000 shares@ HK$0.3310.1% of flowShareXHKGHKEX:DA20250626E00003
  • ▼
    DirectorExecutives
    33,100 HKD11HKEX
    100,000 shares@ HK$0.3310.0% of flowShareXHKGHKEX:DA20250613E00037
  • ▼
    DirectorExecutives
    204,561 HKD11HKEX
    510,000 shares@ HK$0.40110.1% of flowShareXHKGHKEX:DA20241108E00193
  • ▼
    DirectorExecutives
    544,632 HKD11HKEX
    1,320,000 shares@ HK$0.41260.2% of flowShareXHKGHKEX:DA20241107E00385
  • ▼
    DirectorExecutives
    501,336 HKD11HKEX
    880,000 shares@ HK$0.56970.2% of flowShareXHKGHKEX:DA20241105E00086
  • ▼
    DirectorExecutives
    111,300 HKD11HKEX
    210,000 shares@ HK$0.530.0% of flowShareXHKGHKEX:DA20241015E00508
  • ▼
    DirectorExecutives
    308,833 HKD11HKEX
    575,000 shares@ HK$0.53710.1% of flowShareXHKGHKEX:DA20241014E00316
  • ▼
    DirectorExecutives
    171,266 HKD11HKEX
    315,000 shares@ HK$0.54370.1% of flowShareXHKGHKEX:DA20241010E00409
  • ▼
    DirectorExecutives
    349,508 HKD11HKEX
    655,000 shares@ HK$0.53360.1% of flowShareXHKGHKEX:DA20241009E00484
  • ▼
    DirectorExecutives
    538,431 HKD11HKEX
    1,010,000 shares@ HK$0.53310.2% of flowShareXHKGHKEX:DA20241008E00390
  • ▼
    DirectorExecutives
    685,824 HKD11HKEX
    1,410,000 shares@ HK$0.48640.2% of flowShareXHKGHKEX:DA20241007E00217
  • ▼
    DirectorExecutives
    509,000 HKD11HKEX
    1,000,000 shares@ HK$0.5090.2% of flowShareXHKGHKEX:DA20241004E00240
  • ▼
    DirectorExecutives
    866,985 HKD11HKEX
    1,725,000 shares@ HK$0.50260.3% of flowShareXHKGHKEX:DA20241003E00347
  • ▼
    DirectorExecutives
    1M HKD11HKEX
    1,910,000 shares@ HK$0.53860.3% of flowShareXHKGHKEX:DA20241002E00324
  • ▼
    DirectorExecutives
    2,600 HKD11HKEX
    5,000 shares@ HK$0.520.0% of flowShareXHKGHKEX:DA20240930E00324
  • ●
    DirectorExecutives
    0HKEX
    712,099,575 sharesShareXHKGHKEX:DA20230113E00686

24 of 24 declarations

About Guanze Medical Information Industry (Holding) Co., Ltd.

Guanze Medical Information Industry (Holding) Co., Ltd. is a company listed on the Hong Kong Stock Exchange, specializing in medical information services. It focuses on innovation and the development of technological solutions for the healthcare sector.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations